Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Prognostic Factors in DLBCL

January 30th 2020

Treatment of Newly Diagnosed DLBCL

January 30th 2020

The Future Landscape of Follicular Lymphoma Treatment

January 28th 2020

Phase Ib Polatuzumab Vedotin Trial

January 28th 2020

The Phase III GADOLIN Trial

January 28th 2020

Previously Untreated FL: Obinutuzumab Plus Lenalidomide

January 28th 2020

The Phase II EZH2 Inhibitor Trial

January 28th 2020

Sequencing Strategies for Later-Line Therapy

January 28th 2020

The DYNAMO Later-Line Regimen

January 28th 2020

Treatment Options After Second-Line Relapse

January 28th 2020

Relapsed/Refractory Treatment: The MAGNIFY Regimen

January 28th 2020

Determining Second-Line Therapy in FL

January 28th 2020

Phase III GALLIUM Results and Maintenance Therapy

January 28th 2020

Immunochemotherapy Decision Factors

January 28th 2020

When to Initiate Therapy for Follicular Lymphoma

January 28th 2020

The Importance of Risk Assessment

January 28th 2020

Differential Diagnosis and Staging of Follicular Lymphoma

January 28th 2020

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

January 27th 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Dr. Kaplan on Frontline Treatment Options in Follicular Lymphoma

January 18th 2020

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Novel Agents Strengthen Treatment Armamentarium in Non-Hodgkin Lymphoma

January 3rd 2020

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.